| Quarter | Call date | Disclosure | Financial quality | Kept | Missed | |
|---|---|---|---|---|---|---|
| Q2'26 | 2026-07-30 | 4/12 | 3 high, 4 medium, 1 low flags | 3 | 1 | Call sheet → |
| Marked | Status | Promise |
|---|---|---|
| Q2'26 | Pending | High single-digit EBIT growth in 27 and 28 Quietly changed to EBITDA and 'foreseeable future' this quarter |
| Q2'26 | Exceeded | Declining leverage towards 3.0x at year-end 2026 Already at 2.8x but only due to Veolium windfall, not operations |
| Q2'26 | Missed | Gradual EBITDA growth throughout the year Q2 EBITDA of $289M barely above Q1's $288M, not 'gradual growth' |
| Q2'26 | Pending | $25M to integrate HG assets, complete by year-end Claims halfway done but no specific progress metrics given |
| Q2'26 | Delivered | Close HG acquisition ahead of initial expectations Closed in February as promised |
| Q2'26 | Delivered | Successfully navigate adverse winter weather conditions No outages during winter storm Ferg, volumes maintained |
Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.
Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.